tiprankstipranks
Trending News
More News >
Cryosite Limited (AU:CTE)
ASX:CTE
Australian Market

Cryosite Limited (CTE) AI Stock Analysis

Compare
4 Followers

Top Page

AU

Cryosite Limited

(Sydney:CTE)

Rating:66Neutral
Price Target:
AU$1.00
▲(35.14%Upside)
Cryosite Limited demonstrates a solid financial performance, particularly in cash flow generation and profitability, which are key strengths. However, the company's balance sheet shows concerns regarding financial leverage, posing potential risks. Technical analysis reflects a bearish trend, but the valuation is reasonable, with an attractive dividend yield. Overall, the stock presents a balanced profile with opportunities and risks, warranting a cautious but optimistic outlook.

Cryosite Limited (CTE) vs. iShares MSCI Australia ETF (EWA)

Cryosite Limited Business Overview & Revenue Model

Company DescriptionCryosite Limited offers outsourced clinical trials logistic services in Australia. It operates through two segments, Clinical Trials and Biological Services Logistics, and Cord Blood and Tissues Storage. The Clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns management, comparator sourcing, import, export, validated transport, and biological storage solutions to the clinical trials, and research and pharmaceutical industry. The Cord Blood and Tissues Storage segment offers long term storage solutions for cord blood and tissue samples. It serves research, medical, pharmaceutical, veterinary, and biotechnology industries. The company was incorporated in 1999 and is based in South Granville, Australia.
How the Company Makes MoneyCryosite Limited generates revenue primarily through its service offerings in the biostorage and biomanagement sectors. Its key revenue streams include fees from clients for storing biological samples, such as cord blood and tissue, which are often collected for potential future medical use. Additionally, the company earns income by providing specialized biorepository services to support clinical trials and research initiatives, offering storage, logistics, and management of biological specimens. Significant partnerships with healthcare providers, research institutions, and clinical trial organizations enhance its service reach and contribute to its earnings.

Cryosite Limited Financial Statement Overview

Summary
Cryosite Limited presents a robust financial performance with strong revenue growth and profitability improvements. The company excels in cash flow generation, reflecting its operational efficiency. However, the balance sheet indicates financial leverage concerns due to decreasing equity and a rising debt-to-equity ratio, which may pose long-term risks if not addressed. Overall, Cryosite demonstrates promising financial health with a need for careful leverage management.
Income Statement
82
Very Positive
Cryosite Limited shows a strong income statement with consistent revenue growth, evident in a 5.7% increase from 2023 to 2024. The company maintains a healthy gross profit margin of 63.4% in 2024. Net profit margin improved to 14.6% in 2024 from 11.8% in 2023, reflecting effective cost management. EBITDA margin also increased to 23.0%, signaling robust operational efficiency. However, the EBIT margin at 16.3% indicates room for further improvement in operational profitability.
Balance Sheet
68
Positive
Cryosite Limited's balance sheet reveals a challenging equity position, with stockholders' equity declining significantly over the period. The debt-to-equity ratio increased, indicating higher leverage. The equity ratio is low at 7.4%, reflecting potential solvency risks. Despite these challenges, the company has maintained a negative net debt, highlighting strong liquidity with cash reserves exceeding total debt.
Cash Flow
90
Very Positive
The cash flow statement is a strong point for Cryosite Limited, with a substantial increase in free cash flow by 106% from 2023 to 2024. Operating cash flow also improved significantly, more than doubling to $2.9 million. The company effectively generates cash relative to net income, indicating efficient cash management and operational performance.
BreakdownTTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue12.85M12.61M11.94M11.76M10.02M8.92M
Gross Profit7.89M7.99M6.48M6.27M5.31M3.51M
EBITDA2.99M3.04M2.34M2.45M1.65M1.15M
Net Income1.83M1.84M1.41M1.36M652.57K1.48M
Balance Sheet
Total Assets19.09M19.71M22.65M21.50M21.99M23.50M
Cash, Cash Equivalents and Short-Term Investments4.49M4.70M5.73M5.34M3.88M4.06M
Total Debt2.36M2.44M2.61M849.76K1.07M1.26M
Total Liabilities17.77M18.26M19.86M19.64M21.17M23.35M
Stockholders Equity1.31M1.45M2.78M1.86M819.23K154.88K
Cash Flow
Free Cash Flow2.20M2.44M1.19M1.63M80.07K396.54K
Operating Cash Flow2.76M2.90M1.49M2.49M476.96K1.31M
Investing Cash Flow-481.00K727.00K-1.33M-863.19K-396.89K-909.85K
Financing Cash Flow-3.72M-3.50M-768.00K-148.99K-260.78K-254.60K

Cryosite Limited Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.74
Price Trends
50DMA
0.75
Negative
100DMA
0.76
Negative
200DMA
0.80
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
49.06
Neutral
STOCH
57.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CTE, the sentiment is Neutral. The current price of 0.74 is above the 20-day moving average (MA) of 0.74, below the 50-day MA of 0.75, and below the 200-day MA of 0.80, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 49.06 is Neutral, neither overbought nor oversold. The STOCH value of 57.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:CTE.

Cryosite Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AUCTE
66
Neutral
AU$36.36M19.8787.09%2.68%1.86%16.10%
46
Neutral
C$194.28M-4.22-8.60%2.64%13.54%-1.44%
AULDX
45
Neutral
AU$20.96M-51.49%80.84%57.59%
AUIIQ
45
Neutral
AU$42.42M-39.07%26.07%0.85%
AURHY
41
Neutral
AU$15.10M-71.10%76.17%
AUBDX
40
Neutral
AU$23.79M-104.23%-17.26%
AUMAP
39
Underperform
AU$42.75M-33.42%158.37%36.73%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:CTE
Cryosite Limited
0.74
-0.36
-32.73%
AU:BDX
BCAL Diagnostics Limited
0.07
-0.07
-50.00%
AU:RHY
Rhythm Biosciences Ltd.
0.06
0.00
0.00%
AU:LDX
Lumos Diagnostics Holdings Ltd.
0.03
-0.01
-25.00%
AU:IIQ
Inoviq Ltd
0.37
-0.20
-35.09%
AU:MAP
Microba Life Sciences Limited
0.08
-0.10
-55.56%

Cryosite Limited Corporate Events

Cryosite Director Increases Stake with New Share Acquisition
Jul 1, 2025

Cryosite Limited has announced a change in the director’s interest in securities. Mark Kerr, a director of the company, has acquired 75,000 fully paid ordinary shares through on-market purchases, increasing his total holdings. This acquisition reflects a continued investment by the director in the company, potentially signaling confidence in the company’s future performance.

Cryosite Limited Announces Director’s Share Acquisition
Apr 9, 2025

Cryosite Limited announced a change in the director’s interest, with Mark Kerr acquiring an additional 231,453 fully paid ordinary shares, bringing his total to 7,231,453 shares. This change, conducted through both off-market and on-market trades, reflects a strategic move in the company’s governance structure, potentially impacting its market positioning and stakeholder interests.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 08, 2025